These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38943340)

  • 1. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Murakami S; Inoue T; Kuroyanagi K; Kawamura H; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    J Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38943340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Kuroyanagi K; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    Cancer Med; 2024 Jan; 13(1):e6876. PubMed ID: 38133557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
    Matoya S; Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Kuroyanagi K; Kusakabe A; Koguchi H; Hasegawa I; Miyaki T; Tanaka Y; Kondo H; Kimura Y; Ozasa A; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H;
    Hepatol Res; 2023 Jun; 53(6):511-521. PubMed ID: 36723964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.
    Cao F; Shi C; Zhang G; Luo J; Zheng J; Hao W
    BMC Cancer; 2023 Sep; 23(1):873. PubMed ID: 37718456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
    Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Yokohama K; Nishikawa H; Nishimura T; Shimada N; Kawata K; Kosaka H; Naganuma A; Yata Y; Ohama H; Kuroda H; Aoki T; Tanaka K; Tanaka T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M; Kumada T;
    Hepatol Res; 2024 Apr; 54(4):382-391. PubMed ID: 37983642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Kato D; Kusakabe A; Koguchi H; Hasegawa I; Matoya S; Miyaki T; Kimura Y; Tanaka Y; Kondo H; Ozasa A; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H;
    Oncology; 2024; 102(8):676-687. PubMed ID: 38237558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Ishikawa T; Yamazaki S; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2024 Jan; 44(1):361-368. PubMed ID: 38159993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
    Hatanaka T; Naganuma A; Furusawa A; Tamura Y; Saito N; Suzuki Y; Hoshino T; Yata Y; Uraoka T; Kakizaki S
    Oncology; 2023; 101(3):193-202. PubMed ID: 36649691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):698-706. PubMed ID: 35170529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
    Cancer Med; 2022 Oct; 11(20):3796-3808. PubMed ID: 35441477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
    Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
    Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
    Hatanaka T; Naganuma A; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Kakizaki S; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
    Cancer Med; 2023 Feb; 12(4):4259-4269. PubMed ID: 36156452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
    Tanaka T; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M; Kumada T; ;
    Hepatol Res; 2022 Sep; 52(9):773-783. PubMed ID: 35633504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.
    Kondo T; Fujiwara K; Nakagawa M; Fujimoto K; Yumita S; Ishino T; Ogawa K; Iwanaga T; Koroki K; Kanzaki H; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Ogasawara S; Nakamoto S; Chiba T; Kato J; Kato N
    Sci Rep; 2023 Jul; 13(1):11524. PubMed ID: 37460776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
    Shirane Y; Fujii Y; Ono A; Nakahara H; Hayes CN; Miura R; Murakami S; Sakamoto N; Uchikawa S; Fujino H; Nakahara T; Murakami E; Yamauchi M; Miki D; Kawaoka T; Arihiro K; Tsuge M; Oka S
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study.
    Tada T; Kumada T; Hiraoka A; Kariyama K; Tani J; Hirooka M; Takaguchi K; Atsukawa M; Fukunishi S; Itobayashi E; Tsuji K; Tajiri K; Ochi H; Ishikawa T; Yasuda S; Ogawa C; Toyoda H; Hatanaka T; Nishimura T; Kakizaki S; Kawata K; Shimada N; Tada F; Nouso K; Tsutsui A; Ohama H; Morishita A; Nagano T; Itokawa N; Okubo T; Arai T; Kosaka H; Imai M; Naganuma A; Nakamura S; Koizumi Y; Kaibori M; Iijima H; Hiasa Y;
    Cancer Med; 2023 Mar; 12(6):6980-6993. PubMed ID: 36484470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.